Category:Medication templates
 | Templates relating to medication. The pages listed in this category are templates.
This page is part of Wikipedia's administration and not part of the encyclopedia.
Further template category notes
This category contains pages in the template namespace. It should not be used to categorize articles or pages in other namespaces. To add a template to this category:
|
Pages in category "Medication templates"
The following 110 pages are in this category, out of 110 total. This list may not reflect recent changes.
A
- Template:Affinities and estrogenic potencies of estrogen esters and ethers at the estrogen receptors
- Template:Affinities of estrogen receptor ligands for the ERα and ERβ
- Template:Affinities of selected androgen receptor ligands
- Template:Amphetamine base in marketed amphetamine medications
- Template:Androgen replacement therapy formulations and dosages used in men
- Template:Androgen replacement therapy formulations and dosages used in women
- Template:Androgen/anabolic steroid dosages for breast cancer
- Template:Available forms of estradiol
- Template:Available forms of progesterone
- Template:Available forms of testosterone
C
- Template:Chemical structures of equine estrogens
- Template:Chemical structures of major endogenous estrogens
- Template:Chemical structures of major endogenous estrogens medication version
- Template:Classification of estrogens and antiestrogens by receptor–estrogen complex retention
- Template:Comparison of early clinical experience with antiestrogens for advanced breast cancer
- Template:Composition of conjugated estrogens and properties of constituents
E
H
- Template:Hormone levels with estradiol and estradiol esters by intramuscular injection
- Template:Hormone levels with estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone by intramuscular injection
- Template:Hormone levels with gonadotropin-releasing hormone agonists and antagonists
- Template:Hormone levels with nandrolone esters by intramuscular injection
- Template:Hormone levels with oral estradiol
- Template:Hormone levels with sublingual estradiol
- Template:Hormone levels with transdermal estradiol patches
M
P
- Template:Parenteral durations of androgens/anabolic steroids
- Template:Parenteral potencies and durations of nonsteroidal estrogens
- Template:Parenteral potencies and durations of progestogens
- Template:Pharmacodynamics of aromatase inhibitors
- Template:Pharmacodynamics of progestogens
- Template:Pharmacokinetic parameters of progesterone by different routes
- Template:Pharmacokinetics of 100 mg per day spironolactone and its metabolites
- Template:Pharmacokinetics of long-acting injectable antipsychotics
- Template:Pharmacokinetics of progestogens
- Template:Pharmacokinetics of testosterone esters
- Template:Pharmacokinetics of three estradiol esters by intramuscular injection
- Template:Pharmacological properties of major anabolic steroids
- Template:Pharmacology of estrone
- Template:Plasma estrogen levels after a single dose of conjugated estrogens by different routes
- Template:Plasma estrogen levels after a single dose of estradiol by different routes
- Template:Plasma levels and binding potential of flutamide and bicalutamide during first week
- Template:Potencies and durations of natural estrogens by intramuscular injection
- Template:Progesterone metabolism
- Template:Protein binding and metabolic clearance rates of estrogens
- Template:Psilocin activities
- Template:Published case reports of bicalutamide-associated liver injury
- Template:Published case reports of bicalutamide-associated lung toxicity
- Template:Published case reports of cyproterone acetate-associated liver toxicity
- Template:Published case reports of cyproterone acetate-associated meningioma
- Template:Published case reports of cyproterone acetate-associated prolactinoma
R
- Template:Relative affinities of anabolic steroids and related steroids
- Template:Relative affinities of estrogens for steroid hormone receptors and blood proteins
- Template:Relative affinities of first-generation nonsteroidal antiandrogens for the androgen receptor
- Template:Relative affinities of hydroxyprogesterone and related steroids
- Template:Relative affinities of levonorgestrel and metabolites
- Template:Relative affinities of nandrolone and related steroids
- Template:Relative affinities of nandrolone and related steroids at the androgen receptor
- Template:Relative affinities of norethisterone, metabolites, and prodrugs
- Template:Relative affinities of noretynodrel, tibolone, and metabolites
- Template:Relative affinities of normethandrone and metabolites
- Template:Relative androgenic to anabolic activity in animals
- Template:Relative interconversion rates of estradiol, estrone, and estrone sulfate in tissues throughout the body
- Template:Relative oral potencies of estrogens
- Template:Relative potencies of selected antiandrogens
- Template:Results of the Women's Health Initiative menopausal hormone therapy randomized controlled trials
- Template:Risk of breast cancer with menopausal hormone therapy by duration in large observational studies
- Template:Risk of breast cancer with menopausal hormone therapy in large observational studies
- Template:Risk of venous thromboembolism with hormone therapy and birth control pills (QResearch/CPRD)
S
- Template:Selected biological properties of endogenous estrogens in rats
- Template:Side effects of bremelanotide in phase 3 clinical trials
- Template:Side effects of combined androgen blockade with flutamide
- Template:Side effects of combined androgen blockade with nilutamide and a GnRH agonist
- Template:Side effects of combined androgen blockade with nilutamide and surgical castration
- Template:Side effects of combined androgen blockade with nonsteroidal antiandrogens
- Template:Side effects of cyproterone acetate in the SExual-HOrmonal Surveillance STudy (SEHOST)
- Template:Side effects of estradiol undecylate versus cyproterone acetate in men
- Template:Side effects of estramustine phosphate (EMC)
- Template:Side effects of estramustine phosphate (FDA)
- Template:Side effects of estrogen plus high- versus low-dose cyproterone acetate in women
- Template:Side effects of high-dose cyproterone acetate
- Template:Side effects of lower versus higher dose oral estradiol
- Template:Side effects of spironolactone in women in clinical studies for acne
- Template:Spirolactone structures
- Template:Spironolactone at steroid hormone receptors
- Template:Structural aspects of androgens and anabolic steroids
- Template:Structural aspects of progestogens used in clinical and veterinary medicine
- Template:Structural properties of major anabolic steroid esters
- Template:Structural properties of major testosterone esters
- Template:Structural properties of selected estradiol esters
T
- Template:Tamoxifen dosage and incidence of breast symptoms with bicalutamide in men
- Template:Target ranges for hormone levels in hormone therapy for transgender women
- Template:Testosterone levels in males and females
- Template:Testosterone levels with cyproterone acetate
- Template:Testosterone metabolism mini
- Template:Tissue-specific estrogenic and antiestrogenic activity of SERMs
- Template:Transdermal estradiol patches marketed in the United States